Technologies

Allows unmatched flexibility, provides the ability to respond to rapidly changing demands in GMP manufacturing:

NTx’s design uses modular technology that presents a high degree of flexibility and scalability to meet changing production needs. And presents the following advantages:

• Ability to rapidly scale up/scale out to meet changing demand of any given product.
• Disposable technology removes plant bottlenecks associated with CIP/SIP. Also simplifies facility design and start-up requirements for equipment validation and automation. Results in lower capital cost and faster facility build-out.
• A fully closed system enables multi-product manufacturing, a benefit for facilities with a dynamic product portfolio.
• The hardware of the system is modular, so additional post IVT processing and purification can be implemented to meet the requirements of any therapeutic.
• Distributed manufacturing.

Shortens traditionally long discovery and development cycles:

NTx’s adaptable platform technology can be rapidly deployed to synthesize and manufacture different drug candidate, realizing the opportunity to bring more compounds through the development process faster which provides a longer patent life-time in the market.

Overcomes presently high discovery, development and manufacturing costs:

Compared to traditional technology for biologics, adoption of NTx’s system requires less complex equipment and facilities, will capitalize on the ease of increasing manufacturing scale with lower capital expenditure.

Eliminates high dependency on a fragile supply chain:

NTx’s unique design does not require complex and fragile supply chain processes. The NTx consumable kits are assembled using standard, single-use components for a more robust supply chain and a fully controlled vertically integrated supply. Furthermore, NTx produces and provides all the enzymes and reagents required for the procedure which alleviates dependency on third party vendors in the supply chain.

Reduces cost and time of product generation:

NTx’s biomanufacturing process is a closed continuous flow process that requires no material or component handling that inherently reduces risk of contamination. The industry-leading process technology realizes reduced formation of product- and process-related impurities, resulting in higher yield and less purification steps.

Lessens environmental impact of pharmaceutical manufacturing:

NTx’s biomanufacturing technology approach generates a high yield of product with significantly better product/waste ratio, and a much smaller footprint than current large scale processes.

Reduces safety incidents in manufacturing environment:

NTx’s manufacturing technology presents a much safer operational environment. By design, it does not present typical work hazards, such as caustic and solvent exposure, steam/high temperatures, high pressure gases, or ergonomic issues due to bulk material handling.